An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs OBI 833 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Lung cancer
- Focus Adverse reactions; First in man
- Sponsors OBI Pharma
- 09 Jan 2018 Planned number of patients changed from 58 to 25.
- 09 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.